Results 121 to 130 of about 205 (161)

Minor histocompatibility antigens – big in tumour therapy

Trends in Immunology, 2004
Technical advances combined with the deciphering of the human genome have facilitated the identification of the molecular nature of human minor histocompatibility (H) antigens. To date, it is believed that minor H antigens result from just any polymorphic protein, regardless of their functional properties.
Spierings, E., Wieles, B., Goulmy, E.A.J.M.   +2 more
openaire   +3 more sources

Presentation and recognition of major and minor histocompatibility antigens

Transplant Immunology, 1994
The structural basis of allorecognition is heterogeneous. For minor histocompatibility antigen-specific T cells and for a minority of anti-MHC T cells (indirect allorecognition), the allogeneic molecule acts as any other protein, and is processed and presented as a peptide in the context of self MHC.
A N, Warrens, G, Lombardi, R I, Lechler
openaire   +2 more sources

Immunodominant minor histocompatibility antigens: the major ones

Immunology Today, 1998
Abstract Minor histocompatibility antigens (MiHAs) are extremely numerous—possibly up to 720 in mice—and have been regarded as an `immunogenetic nightmare' in transplantation. Here, Claude Perreault, Denis Roy and Claudette Fortin summarize evidence showing that most anti-MiHA T-cell responses are oligoclonal, being restricted to several dominant ...
C, Perreault, D C, Roy, C, Fortin
openaire   +2 more sources

Much ado about minor histocompatibility antigens

Immunology Today, 1998
Abstract Current knowledge of histocompatibility (H) loci located outside of the major histocompatibility complex - i.e. those encoding the so-called minor H antigens - was surveyed at a recent meeting ∗ ∗The 1st International Symposium on Minor Histocompatibility Antigens was held at Bar Harbor, ME, USA, on 14–17 September 1997..
Simpson, E, Roopenian, D, Goulmy, E
openaire   +3 more sources

Molecular Typing Methods for Minor Histocompatibility Antigens

2007
Minor histocompatibility (H) antigens crucially affect the outcome of human leukocyte antigen-matched allogeneic stem cell transplantation. The number of molecularly identified minor H antigens is rapidly increasing. In parallel, clinical implementation of minor H antigens for immunotherapy has gained significant interest.
Eric, Spierings, Els, Goulmy
openaire   +2 more sources

Minor histocompatibility antigens: past, present, and future

Tissue Antigens, 2014
AbstractMinor histocompatibility (H) antigens are key molecules driving allo‐immune responses in both graft‐versus‐host‐disease (GvHD) and in graft‐versus‐leukemia (GvL) reactivity in human leukocyte antigen (HLA)‐matched hematopoietic stem‐cell transplantation (HSCT).
openaire   +2 more sources

Minor Histocompatibility Antigens

The Cancer Journal, 2004
Minor histocompatibility antigens have to be considered as key molecules in the stem cell-based immunotherapy of malignancies. Allogeneic stem cell transplantation (SCT) is a well-established and effective therapy for advanced hematologic malignancies.
openaire   +2 more sources

Molecular Typing Methods for Minor Histocompatibility Antigens

2013
Minor histocompatibility (H) antigen mismatching leads to clinically relevant alloimmune reactivity. Depending on the tissue expression pattern of the involved minor H antigens, the immune response may either cause graft-versus-host disease and a graft-versus-tumor effect or lead to only a graft-versus-leukemia effect. Thus, identification of recipient-
openaire   +2 more sources

IMMUNE RESPONSE TO MINOR HISTOCOMPATIBILITY ANTIGENS

Transplantation, 1972
L W, Schierman, R A, McBride
openaire   +2 more sources

Minor Histocompatibility Antigens

2011
openaire   +2 more sources